California is suing the United States’ leading insulin makers and pharmacy benefit managers, accusing them of using their market power to overcharge patients for the life-saving drug, the state’s attorney general announced on Thursday.
Tag Archive for: Eli Lilly
Following a banner year marked by the approval and launch of its diabetes drug Mounjaro, Eli Lilly revealed at the 41st J.P. Morgan Healthcare Conference that it was preparing for another big year.
The company has entered into a multi-target partnership with Sosei Group to discover, develop and commercialize compounds targeting novel G protein-coupled receptor (GPCR) targets in diabetes and metabolic diseases.
Amgen Inc.’s experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday.
The drug is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.
Nimbus Therapeutics reported positive Phase IIb results on Wednesday for its TYK2 inhibitor, NDI-034858, in moderate-to-severe plaque psoriasis.
Eli Lilly & Co. must pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine whether its migraine drug Emgality infringed three Teva patents, a Boston federal court jury decided on Wednesday.
According to reports, some Eli Lilly and Co employees have requested transfers from the drugmaker’s Indiana operations after the U.S. state’s lawmakers approved a bill that would ban most abortions there.
Boehringer Ingelheim and Eli Lilly said their diabetes drug Jardiance was shown to slow the progression of chronic kidney disease (CKD), as they seek to catch up with market segment leader AstraZeneca.
Eli Lilly and Co. on Tuesday forecast its annual profit and revenue below estimates, as a stronger dollar piled more pressure on the drugmaker struggling with lower insulin prices and generic competition for its cancer drug.